Preclinical analysis of treosulfan in combination with total body irradiation as conditioning regimen prior to bone marrow transplantation in rats

Sender, Vicky and Hofmeister-Mielke, Nicole and Sievert, Kathrin and Teifke, Jens Peter and Vogel, Heike and Baumgart, Joachim and Pichlmeier, Uwe and Freund, Mathias and Casper, Jochen and Wolff, Daniel (2009) Preclinical analysis of treosulfan in combination with total body irradiation as conditioning regimen prior to bone marrow transplantation in rats. IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, 31 (4). pp. 595-600. ISSN 0892-3973, 1532-2513

Full text not available from this repository. (Request a copy)

Abstract

Treosulfan (Treo) and total body irradiation (TBI) demonstrate a high therapeutic activity in treatment of acute leukemia and lymphoma. We investigated the combination of Treo and TBI prior to bone marrow transplantation (BMT) in rats. Female Lewis rats were treated with Treo on 3 consecutive days followed by TBI with either 5 Gy (n = 28) or 7.5 Gy (n = 48). After conditioning animals received 4 x 10E7 bone marrow cells (BC) from female Lewis rats. Additional 16 rats were transplanted with 4 x 10E7 BC and 1.5 x 10E7 spleen T-cells from female Brown-Norway (BN) rats. Animals were examined daily for clinical signs and toxicity was investigated by necropsy and histology in all animals. Gastrointestinal toxicity was the dose-limiting factor of Treo in combination with TBI. The highest tolerable dose of Treo in combination with 7.5 Gy TBI was 3 x 0.5 g/kg and the highest tolerable dose of Treo in combination with 5 Gy TBI was 3 x 0.6 g/kg. Allogeneic BMT from BN donors resulted in engraftment and survival of 12 out of 16 animals. Gastrointestinal toxicity is the dose-limiting factor in the treatment with Treo and TBI. Furthermore, Treo possesses certain characteristics of a radiosensitizer.</.

Item Type: Article
Uncontrolled Keywords: STEM-CELL TRANSPLANTATION; ACUTE MYELOID-LEUKEMIA; I DOSE-ESCALATION; INTRAVENOUS TREOSULFAN; OVARIAN-CARCINOMA; PREPARATIVE REGIMEN; ANTITUMOR-ACTIVITY; CHEMOTHERAPY; FLUDARABINE; BUSULFAN;
Subjects: 600 Technology > 610 Medical sciences Medicine
Divisions: Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie)
Depositing User: Dr. Gernot Deinzer
Date Deposited: 31 Aug 2020 06:56
Last Modified: 31 Aug 2020 06:56
URI: https://pred.uni-regensburg.de/id/eprint/28038

Actions (login required)

View Item View Item